-
Je něco špatně v tomto záznamu ?
Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis
KA. Lang Kuhs, D. Anantharaman, T. Waterboer, M. Johansson, P. Brennan, A. Michel, M. Willhauck-Fleckenstein, MP. Purdue, I. Holcátová, W. Ahrens, P. Lagiou, J. Polesel, L. Simonato, F. Merletti, CM. Healy, K. Kjaerheim, DI. Conway, TV....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, Research Support, N.I.H., Intramural, práce podpořená grantem
NLK
Free Medical Journals
od 1991 do Před 1 rokem
Freely Accessible Science Journals
od 1991 do Před 12 měsíci
Open Access Digital Library
od 1991-11-01
Open Access Digital Library
od 1991-11-01
- MeSH
- dospělí MeSH
- ELISA MeSH
- infekce papilomavirem imunologie MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidský papilomavirus 16 imunologie MeSH
- mladý dospělý MeSH
- nádory orofaryngu imunologie virologie MeSH
- onkogenní proteiny virové imunologie MeSH
- protilátky virové krev MeSH
- represorové proteiny imunologie MeSH
- rizikové faktory MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- spinocelulární karcinom imunologie virologie MeSH
- studie případů a kontrol MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Intramural MeSH
BACKGROUND: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. METHODS: A total of 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having (i) moderate [mean fluorescent intensity (MFI) ≥ 484 and <1,000] or (ii) high seroreactivity (MFI ≥ 1,000). Associations of moderate and high HPV16 E6 seroreactivity with (i) demographic risk factors; and seropositivity for (ii) other HPV16 proteins (E1, E2, E4, E7, and L1), and (iii) E6 proteins from non-HPV16 types (HPV6, 11, 18, 31, 33, 45, and 52) were evaluated. RESULTS: Thirty-two (0.7%) HPV16 E6 seropositive controls were identified; 17 (0.4%) with moderate and 15 (0.3%) with high seroreactivity. High HPV16 E6 seroreactivity was associated with former smoking [odds ratio (OR), 5.5; 95% confidence interval (CI), 1.2-51.8], and seropositivity against HPV16 L1 (OR, 4.8; 95% CI, 1.3-15.4); E2 (OR, 7.7; 95% CI, 1.4-29.1); multiple HPV16 proteins (OR, 25.3; 95% CI, 2.6-119.6 for three HPV16 proteins beside E6) and HPV33 E6 (OR, 17.7; 95% CI, 1.9-81.8). No associations were observed with moderate HPV16 E6 seroreactivity. CONCLUSIONS: High HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not explained by demographic factors. IMPACT: Some HPV16 E6 seropositive individuals without diagnosed HPV-driven cancer, especially those with seropositivity against other HPV16 proteins, may harbor a biologically relevant HPV16 infection.
Charles University Prague 1st Faculty of Medicine Prague Czech Republic
CRO Aviano National Cancer Institute Aviano Italy
Croatian National Institute of Public Health Zagreb Croatia
Danish Cancer Society Research Center Copenhagen Denmark
Department of Clinical Sciences Lund University Lund Sweden
Department of Medical Sciences University of Turin Turin Italy
Department of Research Cancer Registry of Norway Oslo Norway
Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
German Cancer Research Center Heidelberg Germany
Imperial College London London United Kingdom
International Agency for Research on Cancer Lyon France
Leibniz Institute for Prevention Research and Epidemiology Bremen Germany
National Cancer Institute NIH Bethesda Maryland
Trinity College School of Dental Science Dublin Ireland
University of Aberdeen Aberdeen United Kingdom
University of Athens Medical School Athens Greece
University of Glasgow Glasgow United Kingdom University of Aberdeen Aberdeen United Kingdom
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010607
- 003
- CZ-PrNML
- 005
- 20160412120801.0
- 007
- ta
- 008
- 160408s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1158/1055-9965.EPI-14-1217 $2 doi
- 024 7_
- $a 10.1158/1055-9965.EPI-14-1217 $2 doi
- 035 __
- $a (PubMed)25623733
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Lang Kuhs, Krystle A $u National Cancer Institute, NIH, Bethesda, Maryland. Krystle.Kuhs@nih.gov.
- 245 10
- $a Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis / $c KA. Lang Kuhs, D. Anantharaman, T. Waterboer, M. Johansson, P. Brennan, A. Michel, M. Willhauck-Fleckenstein, MP. Purdue, I. Holcátová, W. Ahrens, P. Lagiou, J. Polesel, L. Simonato, F. Merletti, CM. Healy, K. Kjaerheim, DI. Conway, TV. Macfarlane, P. Thomson, X. Castellsagué, A. Znaor, A. Black, WY. Huang, V. Krogh, A. Trichopoulou, HB. Bueno-de-Mesquita, F. Clavel-Chapelon, E. Weiderpass, J. Ekström, E. Riboli, A. Tjønneland, MJ. Sánchez, RC. Travis, A. Hildesheim, M. Pawlita, AR. Kreimer,
- 520 9_
- $a BACKGROUND: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. METHODS: A total of 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having (i) moderate [mean fluorescent intensity (MFI) ≥ 484 and <1,000] or (ii) high seroreactivity (MFI ≥ 1,000). Associations of moderate and high HPV16 E6 seroreactivity with (i) demographic risk factors; and seropositivity for (ii) other HPV16 proteins (E1, E2, E4, E7, and L1), and (iii) E6 proteins from non-HPV16 types (HPV6, 11, 18, 31, 33, 45, and 52) were evaluated. RESULTS: Thirty-two (0.7%) HPV16 E6 seropositive controls were identified; 17 (0.4%) with moderate and 15 (0.3%) with high seroreactivity. High HPV16 E6 seroreactivity was associated with former smoking [odds ratio (OR), 5.5; 95% confidence interval (CI), 1.2-51.8], and seropositivity against HPV16 L1 (OR, 4.8; 95% CI, 1.3-15.4); E2 (OR, 7.7; 95% CI, 1.4-29.1); multiple HPV16 proteins (OR, 25.3; 95% CI, 2.6-119.6 for three HPV16 proteins beside E6) and HPV33 E6 (OR, 17.7; 95% CI, 1.9-81.8). No associations were observed with moderate HPV16 E6 seroreactivity. CONCLUSIONS: High HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not explained by demographic factors. IMPACT: Some HPV16 E6 seropositive individuals without diagnosed HPV-driven cancer, especially those with seropositivity against other HPV16 proteins, may harbor a biologically relevant HPV16 infection.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protilátky virové $x krev $7 D000914
- 650 _2
- $a spinocelulární karcinom $x imunologie $x virologie $7 D002294
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a ELISA $7 D004797
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidský papilomavirus 16 $x imunologie $7 D052162
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a onkogenní proteiny virové $x imunologie $7 D009856
- 650 _2
- $a nádory orofaryngu $x imunologie $x virologie $7 D009959
- 650 _2
- $a infekce papilomavirem $x imunologie $7 D030361
- 650 _2
- $a represorové proteiny $x imunologie $7 D012097
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Intramural $7 D052060
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Anantharaman, Devasena $u International Agency for Research on Cancer (IARC), Lyon, France. $7 gn_A_00005858
- 700 1_
- $a Waterboer, Tim $u German Cancer Research Center (DKFZ), Heidelberg, Germany.
- 700 1_
- $a Johansson, Mattias $u International Agency for Research on Cancer (IARC), Lyon, France.
- 700 1_
- $a Brennan, Paul $u International Agency for Research on Cancer (IARC), Lyon, France.
- 700 1_
- $a Michel, Angelika $u German Cancer Research Center (DKFZ), Heidelberg, Germany.
- 700 1_
- $a Willhauck-Fleckenstein, Martina $u German Cancer Research Center (DKFZ), Heidelberg, Germany.
- 700 1_
- $a Purdue, Mark P $u National Cancer Institute, NIH, Bethesda, Maryland. Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
- 700 1_
- $a Holcátová, Ivana $u Charles University in Prague, 1st Faculty of Medicine, Prague, Czech Republic.
- 700 1_
- $a Ahrens, Wolfgang $u Leibniz Institute for Prevention Research and Epidemiology, Bremen, Germany. $7 gn_A_00002543
- 700 1_
- $a Lagiou, Pagona $u University of Athens Medical School, Athens, Greece.
- 700 1_
- $a Polesel, Jerry $u CRO Aviano National Cancer Institute, Aviano, Italy.
- 700 1_
- $a Simonato, Lorenzo $u Laboratory of Public Health and Population Studies, Department of Molecular Medicine, University of Padova, Padova, Italy.
- 700 1_
- $a Merletti, Franco $u Department of Medical Sciences, University of Turin, Turin, Italy.
- 700 1_
- $a Healy, Claire M $u Trinity College School of Dental Science, Dublin, Ireland.
- 700 1_
- $a Kjaerheim, Kristina $u Department of Research, Cancer Registry of Norway, Oslo, Norway.
- 700 1_
- $a Conway, David I $u University of Glasgow, Glasgow, United Kingdom. University of Aberdeen, Aberdeen, United Kingdom.
- 700 1_
- $a Macfarlane, Tatiana V $u University of Aberdeen, Aberdeen, United Kingdom.
- 700 1_
- $a Thomson, Peter $u University of Newcastle on Tyne, Newcastle, United Kingdom.
- 700 1_
- $a Castellsagué, Xavier $u Unit of Infections and Cancer, Institut Català d'Oncologia (ICO), IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Catalonia, Spain.
- 700 1_
- $a Znaor, Ariana $u Croatian National Institute of Public Health, Zagreb, Croatia.
- 700 1_
- $a Black, Amanda $u National Cancer Institute, NIH, Bethesda, Maryland.
- 700 1_
- $a Huang, Wen-Yi $u National Cancer Institute, NIH, Bethesda, Maryland.
- 700 1_
- $a Krogh, Vittorio $u Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- 700 1_
- $a Trichopoulou, Antonia $u Hellenic Health Foundation, Athens, Greece. Academy of Athens, Athens, Greece. University of Athens Medical School, Athens, Greece.
- 700 1_
- $a Bueno-de-Mesquita, H B As $u National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. University Medical Centre, Utrecht, the Netherlands. The School of Public Health, Imperial College London, London, United Kingdom. University of Malaya, Kuala Lumpur, Malaysia.
- 700 1_
- $a Clavel-Chapelon, Françoise $u Centre for Research in Epidemiology and Population Health (CESP), Villejuif, France. Université Paris Sud, Villejuif, France. Institut Gustave Roussy, Villejuif, France.
- 700 1_
- $a Weiderpass, Elisabete $u Department of Research, Cancer Registry of Norway, Oslo, Norway. Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland.
- 700 1_
- $a Ekström, Johanna $u Department of Clinical Sciences, Lund University, Lund, Sweden.
- 700 1_
- $a Riboli, Elio $u Imperial College London, London, United Kingdom.
- 700 1_
- $a Tjønneland, Anne $u Danish Cancer Society Research Center, Copenhagen, Denmark.
- 700 1_
- $a Sánchez, María-José $u Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
- 700 1_
- $a Travis, Ruth C $u Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
- 700 1_
- $a Hildesheim, Allan $u National Cancer Institute, NIH, Bethesda, Maryland.
- 700 1_
- $a Pawlita, Michael $u German Cancer Research Center (DKFZ), Heidelberg, Germany.
- 700 1_
- $a Kreimer, Aimée R $u National Cancer Institute, NIH, Bethesda, Maryland.
- 773 0_
- $w MED00006442 $t Cancer epidemiology, biomarkers & prevention a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology $x 1538-7755 $g Roč. 24, č. 4 (2015), s. 683-9
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25623733 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160412120844 $b ABA008
- 999 __
- $a ok $b bmc $g 1114036 $s 934975
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 24 $c 4 $d 683-9 $e 20150126 $i 1538-7755 $m Cancer epidemiology, biomarkers & prevention $n Cancer Epidemiol Biomarkers Prev $x MED00006442
- LZP __
- $a Pubmed-20160408
